SALT LAKE CITY, May 17, 2017 -- (Healthcare Sales & Marketing Network) -- Sera Prognostics, Inc., a women’s healthcare company, announced today that Nadia F. Altomare has joined the company as chief commercial officer. Ms. Altomare will lead all commercial activities for Sera as the company makes its groundbreaking PreTRM® test available to physicians and patients. The PreTRM test is the first and only broadly clinically-validated blood test that provides an early and individualized prediction of preterm birth risk. Based on the passage above, Can you provide a brief summary of Sera Prognostics, Inc. and their CEO's announcement regarding their PreTRM® test?
This prompt doesn't seem malicious.